Description: Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with radiation for the treatment of esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for esophageal cancer and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei, Taiwan.
Home Page: www.medigen.com.tw
No.3, Park Street
Taipei,
11503
Taiwan
Phone:
886 2 7736 1234
Officers
| Name | Title |
|---|---|
| Dr. Shi-Chung Chang | Chairman and Chief Exec. Officer |
| Mr. Eugene Cheng | Pres & Director |
| Mr. Bill Ou | Chief Financial Officer |
| Wenlii Lin | Pres of Vaccine Bus. |
Exchange: TWO
Country: TW : Taiwan
Currency: New Taiwan Dollar (NT$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0122 |
| Price-to-Sales TTM: | 1.6598 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |